Marie-Claude Jacques appointed Senior Vice President, Global Sales; Antwan Gipson joins as Senior Vice President, Manufacturing & Operations
Adagio Medical Holdings, Inc., a and leader in catheter ablation technologies for treating cardiac arrhythmias, announced the appointment of two key executives to its senior leadership team. Marie-Claude Jacques joins as Senior Vice President of Global Sales and Antwan Gipson as Senior Vice President of Manufacturing and Operations. These additions come as the company prepares for the commercialization of its proprietary Ultra-Low Temperature Cardiac Ablation technology, also known as ULTC, for electrophysiology applications.
Health Technology Insights: GT Medical Names New GammaTile Center of Excellence
Todd Usen, Chief Executive Officer of Adagio Medical, emphasized that these appointments mark an important step in the company’s commercialization strategy. He noted that Marie-Claude Jacques brings a proven track record of successfully introducing disruptive technologies into the electrophysiology market, most notably during her time at Baylis Medical, which culminated in its acquisition by Boston Scientific. Antwan Gipson brings extensive experience in building scalable and compliant manufacturing operations for high-growth medical technology companies. Usen stated that their combined expertise will be critical as Adagio prepares to launch its ULTC ablation platform globally.
Health Technology Insights: Bioptimus Launches M-Optimus to Transform Biological AI
Marie-Claude Jacques has more than 15 years of experience in commercial leadership roles across electrophysiology and interventional cardiology. Her background includes leading global sales and marketing at Catheter Precision for the launch of the VIVO non-invasive 3D mapping system and the LockeT™ venous closure device. Previously, she served as Vice President of Sales and Marketing at Baylis Medical, building a team of 100 employees and helping scale the company’s electrophysiology and transseptal access business to over $170 million in annual revenue. Following the Baylis acquisition, she held a senior sales role at Boston Scientific. Ms. Jacques holds an MBA from Warwick Business School in the UK, graduate certificates in Business Law from USC Gould School of Law and Business Communication from Harvard Extension School, and recently completed the MIT Sloan Executive Program in Artificial Intelligence in Healthcare. She expressed excitement about joining Adagio and leading the global commercial organization, stating she looks forward to working with electrophysiologists to improve outcomes for patients with complex arr.
Health Technology Insights: PADCEV Plus Keytruda Boosts Survival in Bladder Cancer Patients
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
